These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 37586958)
1. DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study. Toyama K; Eto T; Takazawa K; Shimizu S; Nakayama T; Furihata K; Sogawa Y; Kumazaki M; Jonai N; Matsunaga S; Takeshita F; Yoshihara K; Ishizuka H Vaccine; 2023 Aug; 41(38):5525-5534. PubMed ID: 37586958 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. Eugenia-Toledo-Romaní M; Verdecia-Sánchez L; Rodríguez-González M; Rodríguez-Noda L; Valenzuela-Silva C; Paredes-Moreno B; Sánchez-Ramírez B; Pérez-Nicado R; González-Mugica R; Hernández-García T; Bergado-Baez G; Pi-Estopiñán F; Cruz-Sui O; Fraga-Quintero A; García-Montero M; Palenzuela-Díaz A; Baró-Román G; Mendoza-Hernández I; Fernandez-Castillo S; Climent-Ruiz Y; Santana-Mederos D; Ramírez Gonzalez U; García-Vega Y; Pérez-Massón B; Guang-Wu-Chen ; Boggiano-Ayo T; Ojito-Magaz E; Rivera DG; Valdés-Balbín Y; García-Rivera D; Vérez-Bencomo V; ; Gómez-Maceo Y; Reyes-Matienzo R; Manuel Coviella-Artime J; Morffi-Cinta I; Martínez-Pérez M; Castillo-Quintana I; Garcés-Hechavarría A; Valera-Fernández R; Martínez-Bedoya D; Garrido-Arteaga R; Cardoso-SanJorge F; Quintero Moreno L; Ontivero-Pino I; Teresa Pérez-Guevara M; Morales-García M; Noa-Romero E; Orosa-Vázquez I; Díaz-Hernández M; Rojas G; Tundidor Y; García-López E; Muñoz-Morejon Y; Galano-Frutos E; Rodríguez-Alvarez J; Arteaga A; Medina Nápoles M; Espi Ávila J; Fontanies Fernández M Vaccine; 2022 Jul; 40(31):4220-4230. PubMed ID: 35691871 [TBL] [Abstract][Full Text] [Related]
4. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Chu L; McPhee R; Huang W; Bennett H; Pajon R; Nestorova B; Leav B; Vaccine; 2021 May; 39(20):2791-2799. PubMed ID: 33707061 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity. Pérez-Rodríguez S; de la Caridad Rodríguez-González M; Ochoa-Azze R; Climent-Ruiz Y; Alberto González-Delgado C; Paredes-Moreno B; Valenzuela-Silva C; Rodríguez-Noda L; Perez-Nicado R; González-Mugica R; Martínez-Pérez M; Sánchez-Ramírez B; Hernández-García T; Díaz-Machado A; Tamayo-Rodríguez M; Martín-Trujillo A; Rubino-Moreno J; Suárez-Batista A; Dubed-Echevarría M; Teresa Pérez-Guevara M; Amoroto-Roig M; Chappi-Estévez Y; Bergado-Báez G; Pi-Estopiñán F; Chen GW; Valdés-Balbín Y; García-Rivera D; Verez-Bencomo V Vaccine; 2022 Mar; 40(13):2068-2075. PubMed ID: 35164986 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study. Sáez-Llorens X; Lanata C; Aranguren E; Celis CR; Cornejo R; DeAntonio R; Ecker L; Garrido D; Gil AI; Gonzales M; Hess-Holtz M; Leroux-Roels G; Junker H; Kays SK; Koch SD; Lazzaro S; Mann P; Quintini G; Srivastava B; Vahrenhorst D; von Eisenhart-Rothe P; Wolz OO; Oostvogels L Vaccine X; 2022 Aug; 11():100189. PubMed ID: 35791320 [TBL] [Abstract][Full Text] [Related]
7. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Kremsner PG; Mann P; Kroidl A; Leroux-Roels I; Schindler C; Gabor JJ; Schunk M; Leroux-Roels G; Bosch JJ; Fendel R; Kreidenweiss A; Velavan TP; Fotin-Mleczek M; Mueller SO; Quintini G; Schönborn-Kellenberger O; Vahrenhorst D; Verstraeten T; Alves de Mesquita M; Walz L; Wolz OO; Oostvogels L; Wien Klin Wochenschr; 2021 Sep; 133(17-18):931-941. PubMed ID: 34378087 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638 [TBL] [Abstract][Full Text] [Related]
11. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A; J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM; Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274 [TBL] [Abstract][Full Text] [Related]
18. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Chu L; Vrbicky K; Montefiori D; Huang W; Nestorova B; Chang Y; Carfi A; Edwards DK; Oestreicher J; Legault H; Dutko FJ; Girard B; Pajon R; Miller JM; Das R; Leav B; McPhee R Nat Med; 2022 May; 28(5):1042-1049. PubMed ID: 35241844 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Shu YJ; He JF; Pei RJ; He P; Huang ZH; Chen SM; Ou ZQ; Deng JL; Zeng PY; Zhou J; Min YQ; Deng F; Peng H; Zhang Z; Wang B; Xu ZH; Guan WX; Hu ZY; Zhang JK Chin Med J (Engl); 2021 Jul; 134(16):1967-1976. PubMed ID: 34310400 [TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]